Stephanie Reading

Stephanie Reading

Auto-generated profile, based on publicly available information

Stephanie Reading

Center for Observational Research, Amgen, Inc, Thousand Oaks, CA (S.R., K.O., J.E.).

Research Focus & Metrics

Academic Career Length

36Years (1991-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
24 December 2020 in European Heart Journal
Verified
Journal Article
Open access
PDF file
JSJessica Schubert
Jessica Schubert
BLBertil Lindahl
Bertil Lindahl
HMHåkan Melhus
Håkan Melhus
HRHenrik Renlund
Henrik Renlund
MLMargrét Leosdottir
Margrét Leosdottir
EHEmil Hagström
Emil Hagström
Aims : Clinical trials have demonstrated that a reduction in low-density lipoprotein cholesterol (LDL-C) reduces cardiovascular (CV) events. This has, however, not yet been shown in a real-world setting. We aimed to investigate the association between LDL-C changes and statin intensity with prognosis after a myocardial infarction (MI). Methods and results : Patients admitted with MI were followed for mortality and major CV events. Changes in LDL-C between the MI and a 6- to 10-week follow-up visit were analysed. The associations between quartiles of LDL-C change and statin intensity with outcomes were assessed using adjusted Cox regression analyses. A total of 40 607 patients were followed for a median of 3.78 years. The median change in LDL-C was a 1.20 mmol/L reduction. Patients with larger LDL-C reduction (1.85 mmol/L, 75th percentile) compared with a smaller reduction (0.36 mmol/L, 25th percentile) had lower hazard ratios (HR) for all outcomes (95% confidence interval): composite of CV mortality, MI, and ischaemic stroke 0.77 (0.70–0.84); all-cause mortality 0.71 (0.63–0.80); CV mortality 0.68 (0.57–0.81); MI 0.81 (0.73–0.91); ischaemic stroke 0.76 (0.62–0.93); heart failure hospitalization 0.73 (0.63–0.85), and coronary artery revascularization 0.86 (0.79–0.94). Patients with ≥50% LDL-C reduction using high-intensity statins at discharge had a lower incidence of all outcomes compared with those using a lower intensity statin. Conclusions : Larger early LDL-C reduction and more intensive statin therapy after MI were associated with a reduced hazard of all CV outcomes and all-cause mortality. This supports clinical trial data suggesting that earlier lowering of LDL-C after an MI confers the greatest benefit.

1 January 2014 in Psychological Trauma: Theory, Research, Practice, and Policy
Verified
Journal Article
Closed access
CLChristopher M. Layne
Christopher M. Layne
JGJohanna K. P. Greeson
Johanna K. P. Greeson
SOSarah A. Ostrowski
Sarah A. Ostrowski
SKSoeun Kim
Soeun Kim
SRStephanie Reading
Stephanie Reading
RPRobert S. Pynoos
Robert S. Pynoos

1 April 2007 in Obesity Surgery
Verified
Journal Article
Closed access
PDF file
MCMatthew Clark
Matthew Clark
BHBarbara K. Hanna
Barbara K. Hanna
JMJane L. Mai
Jane L. Mai
KGKaren M. Graszer
Karen M. Graszer
JKJeanne Graner Krochta
Jeanne Graner Krochta
MSMichael G. Sarr
Michael G. Sarr

30 September 2005 in Body Image
Verified
Journal Article
Closed access
MCMatthew M. Clark
Matthew M. Clark
ICIvana T. Croghan
Ivana T. Croghan
SRStephanie Reading
Stephanie Reading
DSDarrell R. Schroeder
Darrell R. Schroeder
SSSarah M. Stoner
Sarah M. Stoner
KVKristin S. Vickers
Kristin S. Vickers

31 July 2009 in The Journal of Rheumatology
Verified
Journal Article
Closed access
PDF file
SRStephanie R. Reading
Stephanie R. Reading
CCCynthia S. Crowson
Cynthia S. Crowson
RRRichard J. Rodeheffer
Richard J. Rodeheffer
PFPatrick D. Fitz-Gibbon
Patrick D. Fitz-Gibbon
HMHilal Maradit-Kremers
Hilal Maradit-Kremers
SGSherine E. Gabriel
Sherine E. Gabriel
Objective.: Patients with rheumatoid arthritis (RA) have an increased risk for developing cardiovascular disease (CVD) compared to subjects in the general population. The development of CVD has also been linked to chronic sleep apnea. The purpose of this study was to examine the risk for sleep apnea in patients with RA compared to subjects without RA.Methods.: We recruited RA patients and non-RA subjects who were age and sex matched from the same population. These persons completed the Berlin Sleep Questionnaire, which evaluated their level of risk (high or low) for sleep apnea. In addition, there were 3 subscales evaluating snoring, fatigue, and relevant comorbidities [i.e., high blood pressure and obesity [body mass index (BMI) ≥ 30 kg/m2)]. Chi-squared tests were used for comparisons.Results.: The study population consisted of 164 patients with RA and 328 patients without RA. Age, sex and BMI were similar for both groups. There was no difference in snoring (p = 0.31) or in the comorbidities subscale (p = 0.37). However, RA patients reported more fatigue (38%) than subjects without RA (13%; p < 0.001). Overall, the risk for sleep apnea was significantly higher for the RA patients (50%) than the non-RA subjects (31%; p < 0.001).Conclusion.: Patients with RA may be at a higher risk for sleep apnea compared to non-RA subjects. This apparent risk difference may be attributed to reports of fatigue in RA patients, which may be associated with sleep apnea or RA disease itself.

1 December 2022 in Circulation: Cardiovascular Quality and Outcomes
Verified
Journal Article
Closed access
PDF file
AZAlexander R. Zheutlin
Alexander R. Zheutlin
CDCatherine G. Derington
Catherine G. Derington
JHJennifer S. Herrick
Jennifer S. Herrick
RRRobert S. Rosenson
Robert S. Rosenson
BPBharat Poudel
Bharat Poudel
ABAdam P. Bress
Adam P. Bress
Background: Understanding how statins, ezetimibe, and PCSK9i (proprotein convertase subtilisin/kexin type 9 serine protease inhibitors) are prescribed after a myocardial infarction (MI) or elective coronary revascularization may improve lipid-lowering therapy (LLT) intensification and reduce recurrent atherosclerotic cardiovascular disease events. We described the use and intensification of LLT among US veterans who had a MI or elective coronary revascularization between July 24, 2015, and December 9, 2019, within 12 months of hospital discharge. Methods: LLT intensification was defined as increasing statin dose, or initiating a statin, ezetimibe, or a PCSK9i, overall and among those with an LDL-C (low-density lipoprotein cholesterol) ≥ 70 or 100 mg/dL. Poisson regression was used to determine patient characteristics associated with a greater likelihood of LLT intensification following hospitalization for MI or elective coronary revascularization. Results: Among 81 372 index events (mean age, 69.0 years, 2.3% female, mean LDL-C 89.6 mg/dL, 33.8% with LDL-C <70 mg/dL), 39.7% were not taking any LLT, and 22.0%, 37.2%, and 0.6% were taking a low-moderate intensity statin, a high-intensity statin, and ezetimibe, respectively, before MI/coronary revascularization during the study period. Within 14 days, 3 months, and 12 months posthospitalization, 33.3%, 41.9%, and 47.3%, respectively, of veterans received LLT intensification. LLT intensification was most common among veterans taking no LLT (82.5%, n=26 637) before MI/coronary revascularization. Higher baseline LDL-C, having a lipid test, and attending a cardiology visit were each associated with a greater likelihood of LLT intensification, while age ≥ 75 versus <65 years was associated with a lower likelihood of LLT intensification within 12 months posthospitalization. Conclusions: Less than half of veterans received LLT intensification in the year after MI or coronary revascularization suggesting a missed opportunity to reduce atherosclerotic cardiovascular disease risk.